Company Profile · Healthcare

Bio-Techne Corp

TECH · US
Exchange
US
Country
USA
IPO date
Feb 9, 1989
Employees
3,100
Current Price
$57.94
Live · Jun 18, 2026
Fair Buy
≤ $35
Margin-of-safety entry
Baillie Growth Score
27/100
Poor
Intrinsic Value · Three-Tier Range Current price $57.94 Live · Above the optimistic ceiling · future growth overdrawn

Composite valuation range · conservative $24–$30 / fair $31–$42 / optimistic $45–$56. At $57.94, Above the optimistic ceiling · future growth overdrawn.

At publication $51.68 (May 31, 2026)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Market cap$8.61B
Revenue (TTM)$1.21B
EBITDA$366.04M
Profit margin9.05%
ROE5.34%
P/E (TTM)78.57
Forward P/E26.95
PEG0.76
EPS$0.70
Dividend yield0.57%
52-week range$43.12 – $71.93
Analyst target$61.69
Analyst rating4.1 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.